Cuba Leads Anti-Cancer Vaccines Participants in the 2006 International Immunotherapy Event taking place in the Cuban capital exchanged experiences with the results of the clinical tests of HR3 in China and India, where it has helped to treat head and neck tumors and pharynx carcinoma.
Similarly the institution works on clinical tests of the antibody T1, a provisional name for the treatment of self-immune diseases, and of another against breast cancer.
In addition, the CIM has another five similar products under pre-clinical tests.
Therapeutic vaccines against cancer have been relatively unpopular in world clinical practice, but Lage highlighted that Cuba counts on a group of them in different test phases on humans.
CIM = Center of Molecular Immunology - Havana, Cuba
This was discussed at the International Congress "Biotecnología 2006" underway in Havana, Cuba now.
US researchers were banned from attending this international comgress by Bushco's Office of Foreign Assets Control (a branch of the Treasury Dept.).
US Scientists Miss Cuba ExchangeA dozen US researchers were unable to attend the International Congress "Biotecnología 2006," with sessions continuing in this capital Wednesday, after being denied permission from the Office of Foreign Assets Control.
The refusal to authorize the trip of those scientists is due to restrictions imposed by that country's (the USA) blockade, recently condemned for the 15th consecutive year at the UN General Assembly.
The forum presented on Tuesday a new synthetic product with anti-tumoral properties patented by a team of Cuban scientists from the Havana-based Center for Genetic Engineering and Biotechnology (CIGB).
Printer-friendly format
Email this thread to a friend
Bookmark this thread
(1000+ posts)
Send PM |
Profile |
Ignore
